Entrada Therapeutics (TRDA) Cash from Operations (2020 - 2026)

Entrada Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 41695000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 8.28% year-over-year to 41695000.0 in Q1 2026; TTM through Mar 2026 was 131700000.0, a 141.45% decrease from a year earlier, with the FY2025 full-year figure at 128512000.0, down 209.24% from the prior year.
• Cash from Operations eased to 41695000.0 in Q1 2026 per TRDA's latest filing, from 32203000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 203399000.0 in Q1 2023 and bottomed at 41695000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 27304000.0 (2022), against an average of 9749823.53.
• Across the five-year window, Cash from Operations jumped 1068.98% in 2023 and tumbled 687.57% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 27304000.0 in 2022, then surged by 85.3% to 4013000.0 in 2023, then tumbled by 687.57% to 31605000.0 in 2024, then slipped by 1.89% to 32203000.0 in 2025, then dropped by 29.48% to 41695000.0 in 2026.
• Per Business Quant, the three latest TRDA Cash from Operations figures stand at 41695000.0 (Q1 2026), 32203000.0 (Q4 2025), and 28313000.0 (Q3 2025).